- Record: found
- Abstract: found
- Article: found
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
review-article
02 February 2021
Chinese medicine,
Herbal medicine,
Diabetic nephropathy,
Diabetic kidney disease,
Signaling pathway,
Molecular target,
α-SMA, α smooth muscle actin,
ACEI, angiotensin-converting enzyme inhibitor,
ADE, adverse event,
AGEs, advanced glycation end-products,
ATK, protein kinase B,
AM, mesangial area,
AMPKα, adenosine monophosphate-activated protein kinase α,
ARB, angiotensin receptor blocker,
AREs, antioxidant response elements,
BAX, BCL-2-associated X protein,
BCL-2, B-cell lymphoma 2,
BCL-XL, B-cell lymphoma-extra large,
BMP-7, bone morphogenetic protein-7,
BUN, blood urea nitrogen,
BW, body weight,
C, control group,
cAMP, cyclic adenosine monophosphate,
CCR, creatinine clearance rate,
CD2AP, CD2-associated protein,
CHOP, C/EBP homologous protein,
CI, confidence interval,
COL-I/IV, collagen I/IV,
CRP, C-reactive protein,
CTGF, connective tissue growth factor,
D, duration,
DAG, diacylglycerol,
DG, glomerular diameter,
DKD, diabetic kidney disease,
DM, diabetes mellitus,
DN, diabetic nephropathy,
eGFR, estimated GFR,
eIF2α, eukaryotic initiation factor 2α,
EMT, epithelial-to-mesenchymal transition,
EP, E-prostanoid receptor,
ER, endoplasmic reticulum,
ESRD, end-stage renal disease,
ET-1, endothelin-1,
ETAR, endothelium A receptor,
FBG, fasting blood glucose,
FN, fibronectin,
Gαq, Gq protein alpha subunit,
GCK, glucokinase,
GCLC, glutamate-cysteine ligase catalytic subunit,
GFR, glomerular filtration rate,
GLUT4, glucose transporter type 4,
GPX, glutathione peroxidase,
GRB 10, growth factor receptor-bound protein 10,
GRP78, glucose-regulated protein 78,
GSK-3, glycogen synthase kinase 3,
HbA1c, glycosylated hemoglobin,
HDL-C, high density lipoprotein-cholesterol,
HO-1, heme oxygenase-1,
ICAM-1, intercellular adhesion molecule-1,
IGF-1, insulin-like growth factor 1,
IGF-1R, insulin-like growth factor 1 receptor,
IκB-α, inhibitory protein α,
IKK-β, IκB kinase β,
IL-1β/6, interleukin 1β/6,
IR, insulin receptor,
IRE-1α, inositol-requiring enzyme-1α,
IRS, insulin receptor substrate,
JAK, Janus kinase,
JNK, c-Jun N-terminal kinase,
LC3, microtubule-associated protein light chain 3,
LDL, low-density lipoprotein,
LDL-C, low density lipoprotein-cholesterol,
LOX1, lectin-like oxidized LDL receptor 1,
MAPK, mitogen-activated protein kinase,
MCP-1, monocyte chemotactic protein-1,
MD, mean difference,
MDA, malondialdehyde,
MMP-2, matrix metallopeptidase 2,
mTOR, mammalian target of rapamycin,
MYD88, myeloid differentiation primary response 88,
N/A, not applicable,
N/O, not observed,
NOX-4, nicotinamide adenine dinucleotide phosphate-oxidase-4,
NQO1, NAD(P)H:quinone oxidoreductase 1,
N/R, not reported,
NRF2, nuclear factor erythroid 2-related factor 2,
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells,
OCP, oxidative carbonyl protein,
ORP150, 150-kDa oxygen-regulated protein,
p62, sequestosome 1 protein,
P70S6K, 70-kDa ribosomal protein S6 kinase,
PAI-1, plasminogen activator inhibitor-1,
PARP, poly(ADP-Ribose) polymerase,
PBG, postprandial blood glucose,
PERK, protein kinase RNA-like eukaryotic initiation factor 2A kinase,
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1α,
PGE2, prostaglandin E2,
PI3K, phosphatidylinositol 3 kinases,
PINK1, PTEN-induced putative kinase 1,
p-IRS1, phospho-IRS1,
PKC, protein kinase C,
PTEN, phosphatase and tensin homolog,
RAGE, receptors of AGE,
RASI, renin-angiotensin system inhibitor,
RCT, randomized clinical trial,
ROS, reactive oxygen species,
SCr, serum creatinine,
SD, standard deviation,
SD-rat, Sprague–Dawley rat,
SIRT1, sirtuin 1,
SMAD, small mothers against decapentaplegic,
SMD, standard mean difference,
SMURF-2, SMAD ubiquitination regulatory factor 2,
SOCS, suppressor of cytokine signaling proteins,
SOD, superoxide dismutase,
STAT, signal transducers and activators of transcription,
STZ, streptozotocin,
T, treatment group,
TBARS, thiobarbituric acid-reactive substance,
TC, total cholesterol,
TCM, traditional Chinese medicine,
TFEB, transcription factor EB,
TG, triglyceride,
TGBM, thickness of glomerular basement membrane,
TGF-β, tumor growth factor β,
TGFβR-I/II, TGF-β receptor I/II,
TII, tubulointerstitial injury index,
TLR-2/4, toll-like receptor 2/4,
TNF-α, tumor necrosis factor α,
TRAF5, tumor-necrosis factor receptor-associated factor 5,
UACR, urinary albumin to creatinine ratio,
UAER, urinary albumin excretion rate,
UMA, urinary microalbumin,
UP, urinary protein,
VCAM-1, vascular cell adhesion molecule-1,
VEGF, vascular endothelial growth factor,
WMD, weight mean difference,
XBP-1, spliced X box-binding protein 1
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.
Graphical abstract
Diabetic nephropathy is one of the most severe complications of diabetes mellitus. Chinese medicines have been intensively studied in treating diabetic nephropathy. This review comprehensively summarizes and discusses the clinical efficacies and underlying mechanisms of Chinese medicines for diabetic nephropathy, providing deep insights and profound perspectives into this field.
Related collections
Most cited references152
- Record: found
- Abstract: found
- Article: not found
Diabetic kidney disease
Merlin Thomas, Michael Brownlee, Katalin Susztak … (2015)
- Record: found
- Abstract: not found
- Article: not found
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Tobias Huber, Berend Isermann, Mario Schiffer … (2018)
- Record: found
- Abstract: found
- Article: not found
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Mitsuo Kato, Rama Natarajan (2019)
Author and article information
chinese medicine,herbal medicine,diabetic nephropathy,diabetic kidney disease,signaling pathway,molecular target,α-sma, α smooth muscle actin,acei, angiotensin-converting enzyme inhibitor,ade, adverse event,ages, advanced glycation end-products,atk, protein kinase b,am, mesangial area,ampkα, adenosine monophosphate-activated protein kinase α,arb, angiotensin receptor blocker,ares, antioxidant response elements,bax, bcl-2-associated x protein,bcl-2, b-cell lymphoma 2,bcl-xl, b-cell lymphoma-extra large,bmp-7, bone morphogenetic protein-7,bun, blood urea nitrogen,bw, body weight,c, control group,camp, cyclic adenosine monophosphate,ccr, creatinine clearance rate,cd2ap, cd2-associated protein,chop, c/ebp homologous protein,ci, confidence interval,col-i/iv, collagen i/iv,crp, c-reactive protein,ctgf, connective tissue growth factor,d, duration,dag, diacylglycerol,dg, glomerular diameter,dkd, diabetic kidney disease,dm, diabetes mellitus,dn, diabetic nephropathy,egfr, estimated gfr,eif2α, eukaryotic initiation factor 2α,emt, epithelial-to-mesenchymal transition,ep, e-prostanoid receptor,er, endoplasmic reticulum,esrd, end-stage renal disease,et-1, endothelin-1,etar, endothelium a receptor,fbg, fasting blood glucose,fn, fibronectin,gαq, gq protein alpha subunit,gck, glucokinase,gclc, glutamate-cysteine ligase catalytic subunit,gfr, glomerular filtration rate,glut4, glucose transporter type 4,gpx, glutathione peroxidase,grb 10, growth factor receptor-bound protein 10,grp78, glucose-regulated protein 78,gsk-3, glycogen synthase kinase 3,hba1c, glycosylated hemoglobin,hdl-c, high density lipoprotein-cholesterol,ho-1, heme oxygenase-1,icam-1, intercellular adhesion molecule-1,igf-1, insulin-like growth factor 1,igf-1r, insulin-like growth factor 1 receptor,iκb-α, inhibitory protein α,ikk-β, iκb kinase β,il-1β/6, interleukin 1β/6,ir, insulin receptor,ire-1α, inositol-requiring enzyme-1α,irs, insulin receptor substrate,jak, janus kinase,jnk, c-jun n-terminal kinase,lc3, microtubule-associated protein light chain 3,ldl, low-density lipoprotein,ldl-c, low density lipoprotein-cholesterol,lox1, lectin-like oxidized ldl receptor 1,mapk, mitogen-activated protein kinase,mcp-1, monocyte chemotactic protein-1,md, mean difference,mda, malondialdehyde,mmp-2, matrix metallopeptidase 2,mtor, mammalian target of rapamycin,myd88, myeloid differentiation primary response 88,n/a, not applicable,n/o, not observed,nox-4, nicotinamide adenine dinucleotide phosphate-oxidase-4,nqo1, nad(p)h:quinone oxidoreductase 1,n/r, not reported,nrf2, nuclear factor erythroid 2-related factor 2,nf-κb, nuclear factor kappa-light-chain-enhancer of activated b cells,ocp, oxidative carbonyl protein,orp150, 150-kda oxygen-regulated protein,p62, sequestosome 1 protein,p70s6k, 70-kda ribosomal protein s6 kinase,pai-1, plasminogen activator inhibitor-1,parp, poly(adp-ribose) polymerase,pbg, postprandial blood glucose,perk, protein kinase rna-like eukaryotic initiation factor 2a kinase,pgc-1α, peroxisome proliferator-activated receptor gamma coactivator 1α,pge2, prostaglandin e2,pi3k, phosphatidylinositol 3 kinases,pink1, pten-induced putative kinase 1,p-irs1, phospho-irs1,pkc, protein kinase c,pten, phosphatase and tensin homolog,rage, receptors of age,rasi, renin-angiotensin system inhibitor,rct, randomized clinical trial,ros, reactive oxygen species,scr, serum creatinine,sd, standard deviation,sd-rat, sprague–dawley rat,sirt1, sirtuin 1,smad, small mothers against decapentaplegic,smd, standard mean difference,smurf-2, smad ubiquitination regulatory factor 2,socs, suppressor of cytokine signaling proteins,sod, superoxide dismutase,stat, signal transducers and activators of transcription,stz, streptozotocin,t, treatment group,tbars, thiobarbituric acid-reactive substance,tc, total cholesterol,tcm, traditional chinese medicine,tfeb, transcription factor eb,tg, triglyceride,tgbm, thickness of glomerular basement membrane,tgf-β, tumor growth factor β,tgfβr-i/ii, tgf-β receptor i/ii,tii, tubulointerstitial injury index,tlr-2/4, toll-like receptor 2/4,tnf-α, tumor necrosis factor α,traf5, tumor-necrosis factor receptor-associated factor 5,uacr, urinary albumin to creatinine ratio,uaer, urinary albumin excretion rate,uma, urinary microalbumin,up, urinary protein,vcam-1, vascular cell adhesion molecule-1,vegf, vascular endothelial growth factor,wmd, weight mean difference,xbp-1, spliced x box-binding protein 1
chinese medicine, herbal medicine, diabetic nephropathy, diabetic kidney disease, signaling pathway, molecular target, α-sma, α smooth muscle actin, acei, angiotensin-converting enzyme inhibitor, ade, adverse event, ages, advanced glycation end-products, atk, protein kinase b, am, mesangial area, ampkα, adenosine monophosphate-activated protein kinase α, arb, angiotensin receptor blocker, ares, antioxidant response elements, bax, bcl-2-associated x protein, bcl-2, b-cell lymphoma 2, bcl-xl, b-cell lymphoma-extra large, bmp-7, bone morphogenetic protein-7, bun, blood urea nitrogen, bw, body weight, c, control group, camp, cyclic adenosine monophosphate, ccr, creatinine clearance rate, cd2ap, cd2-associated protein, chop, c/ebp homologous protein, ci, confidence interval, col-i/iv, collagen i/iv, crp, c-reactive protein, ctgf, connective tissue growth factor, d, duration, dag, diacylglycerol, dg, glomerular diameter, dkd, diabetic kidney disease, dm, diabetes mellitus, dn, diabetic nephropathy, egfr, estimated gfr, eif2α, eukaryotic initiation factor 2α, emt, epithelial-to-mesenchymal transition, ep, e-prostanoid receptor, er, endoplasmic reticulum, esrd, end-stage renal disease, et-1, endothelin-1, etar, endothelium a receptor, fbg, fasting blood glucose, fn, fibronectin, gαq, gq protein alpha subunit, gck, glucokinase, gclc, glutamate-cysteine ligase catalytic subunit, gfr, glomerular filtration rate, glut4, glucose transporter type 4, gpx, glutathione peroxidase, grb 10, growth factor receptor-bound protein 10, grp78, glucose-regulated protein 78, gsk-3, glycogen synthase kinase 3, hba1c, glycosylated hemoglobin, hdl-c, high density lipoprotein-cholesterol, ho-1, heme oxygenase-1, icam-1, intercellular adhesion molecule-1, igf-1, insulin-like growth factor 1, igf-1r, insulin-like growth factor 1 receptor, iκb-α, inhibitory protein α, ikk-β, iκb kinase β, il-1β/6, interleukin 1β/6, ir, insulin receptor, ire-1α, inositol-requiring enzyme-1α, irs, insulin receptor substrate, jak, janus kinase, jnk, c-jun n-terminal kinase, lc3, microtubule-associated protein light chain 3, ldl, low-density lipoprotein, ldl-c, low density lipoprotein-cholesterol, lox1, lectin-like oxidized ldl receptor 1, mapk, mitogen-activated protein kinase, mcp-1, monocyte chemotactic protein-1, md, mean difference, mda, malondialdehyde, mmp-2, matrix metallopeptidase 2, mtor, mammalian target of rapamycin, myd88, myeloid differentiation primary response 88, n/a, not applicable, n/o, not observed, nox-4, nicotinamide adenine dinucleotide phosphate-oxidase-4, nqo1, nad(p)h:quinone oxidoreductase 1, n/r, not reported, nrf2, nuclear factor erythroid 2-related factor 2, nf-κb, nuclear factor kappa-light-chain-enhancer of activated b cells, ocp, oxidative carbonyl protein, orp150, 150-kda oxygen-regulated protein, p62, sequestosome 1 protein, p70s6k, 70-kda ribosomal protein s6 kinase, pai-1, plasminogen activator inhibitor-1, parp, poly(adp-ribose) polymerase, pbg, postprandial blood glucose, perk, protein kinase rna-like eukaryotic initiation factor 2a kinase, pgc-1α, peroxisome proliferator-activated receptor gamma coactivator 1α, pge2, prostaglandin e2, pi3k, phosphatidylinositol 3 kinases, pink1, pten-induced putative kinase 1, p-irs1, phospho-irs1, pkc, protein kinase c, pten, phosphatase and tensin homolog, rage, receptors of age, rasi, renin-angiotensin system inhibitor, rct, randomized clinical trial, ros, reactive oxygen species, scr, serum creatinine, sd, standard deviation, sd-rat, sprague–dawley rat, sirt1, sirtuin 1, smad, small mothers against decapentaplegic, smd, standard mean difference, smurf-2, smad ubiquitination regulatory factor 2, socs, suppressor of cytokine signaling proteins, sod, superoxide dismutase, stat, signal transducers and activators of transcription, stz, streptozotocin, t, treatment group, tbars, thiobarbituric acid-reactive substance, tc, total cholesterol, tcm, traditional chinese medicine, tfeb, transcription factor eb, tg, triglyceride, tgbm, thickness of glomerular basement membrane, tgf-β, tumor growth factor β, tgfβr-i/ii, tgf-β receptor i/ii, tii, tubulointerstitial injury index, tlr-2/4, toll-like receptor 2/4, tnf-α, tumor necrosis factor α, traf5, tumor-necrosis factor receptor-associated factor 5, uacr, urinary albumin to creatinine ratio, uaer, urinary albumin excretion rate, uma, urinary microalbumin, up, urinary protein, vcam-1, vascular cell adhesion molecule-1, vegf, vascular endothelial growth factor, wmd, weight mean difference, xbp-1, spliced x box-binding protein 1